Bio-Techne

Current directors and officers who also hold a role at another S&P 500 company.

• Julie L. BushmanPSX · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Jun 26, 2026

   On June 23, 2026, in connection with the contemplated Merger, the Compensation Committee of the Board (the “ Compensation Committee ”) approved cash retention bonus awards to each of the Company’s current named executive officers pursuant to retention agreements (the “ Retention Agreements ”) in order to encourage the Company’s named executive officers to remain with the Company and motivate their continued strong performance until the Effective Time. The Retention Agreements became effective only upon the execution of the Merger Agreement. The Compensation Committee approved the following lump sum cash bonus amounts (the “ Retention Bonuses ”) payable to the Company’s named executive officers under the Retention Agreements: Kim Kelderman – $2,120,976; Jim Hippel – $1,541,510; William Geist – $1,161,014; Shane Bohnen – $971,097; and Steve Crouse – $910,263.

   Read the 8-K filing
2. Feb 11, 2026

   Officer Transition On February 11, 2026, Bio-Techne Corporation (the “Company”) announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition. In addition, the Company announced the appointment of Mr. Steve Crouse, age 52, as President, Diagnostics and Spatial Biology Segment (“DSS President”) effective March 1, 2026. Mr. Crouse currently serves as Senior Vice President of Bio-Techne’s Analytical Solutions Division.

   Read the 8-K filing
3. Mar 4, 2025

   As previously disclosed in the Quarterly Report of Bio-Techne Corporation (the “Company”) for the quarter ended September 30, 2024 and filed with the U.S. Securities and Exchange Commission on November 5, 2024, the expiration dates with respect to 794,400 shares subject to outstanding vested options held by former employees was under dispute. In 2017, Charles R. Kummeth, former President and Chief Executive Officer of the Company, was granted options to purchase 779,084 shares of common stock (the “Options”), subject to certain vesting requirements that ultimately were satisfied in accordance with the terms of the underlying award agreements (the “Award Agreements”).

   Read the 8-K filing
4. Feb 5, 2025

   On January 30, 2025, Bio-Techne Corporation (the “Company”) appointed Dr. Amy Herr to the Company’s Board of Directors as an independent director. Dr. Herr’s tenure as a director will begin on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Amy E. Herr, Ph.D., is currently a Chancellor’s Professor of Bioengineering at the University of California, Berkeley and the Vice President of Chan Zuckerberg Biohub Network, a group of nonprofit research institutes that focuses on understanding underlying mechanisms of disease and developing new technologies that will lead to actionable diagnostics and effective therapies. Dr. Herr holds a Master of Science degree and a Doctor of Philosophy degree from Stanford University. Dr.

   Read the 8-K filing
5. Nov 5, 2024

   On October 30, 2024, the Compensation Committee of the Board of Directors of Bio-Techne Corporation (the “Company”) granted James Hippel, the Company’s Executive Vice President, Chief Financial Officer, a one-time restricted stock unit award in the amount of 34,634 shares pursuant to the Company’s 2020 Equity Incentive Plan, as amended to date (the “Plan”). The restricted stock unit award will vest in equal installments on the first three anniversaries of the grant date, subject to Mr. Hippel’s continued service with the Company and the terms of the Plan and the underlying award agreement. The restricted stock unit award was granted for purposes of retention and after considering stock options that Mr. Hippel forfeited due to a stock plan administrative error in recording the expiration date.

   Read the 8-K filing
6. Apr 30, 2024

   On April 24, 2024, Bio-Techne Corporation (the “Company”) temporarily expanded the size of the Board of Directors from ten to eleven members and appointed Dr. Judith Klimovsky to the company's Board of Directors as an independent director. Judith Klimovsky, M.D., is currently the Executive Vice President and Chief Development Officer at Genmab A/S, a Denmark-based biotechnology company. Before joining Genmab A/S, Dr. Klimovsky held various senior global clinical and research positions at Novartis Oncology, a division of Novartis AG, and Bristol-Meyers Squibb Company. Dr. Klimovsky holds an MD from the Universidad de Buenos Aires. There are no arrangements or understandings between Dr. Klimovsky and any other persons pursuant to which she was selected as a director. Additionally, there are no transactions involving the Company and Dr.

   Read the 8-K filing
7. Jan 8, 2024

   Officer Appointment On January 5, 2024, Bio-Techne Corporation (the “Company”) announced the appointment of Dr. Matthew McManus, age 55, as President – Diagnostics and Genomics Segment (“President DGS”) effective January 8, 2024. Dr. McManus recently served as Chief Operating Officer of Azenta, Inc. from January 2022 to October 2022 and has served as a strategic advisor to the Azenta CEO since October 2022. Dr. McManus was previously Senior Vice President and General Manager of the Molecular Diagnostics Division at the Company from September 2021 to January 2022 following the Company’s acquisition of Asuragen, where Dr. McManus had previously served as President and CEO beginning in August 2014. Employment Terms On January 4, 2024, Dr.

   Read the 8-K filing
8. Oct 19, 2023

   Director and Officer Transition On October 19, 2023, Bio-Techne Corporation (the “Company”) announced its succession plan for the Chief Executive Officer position in connection with the previously announced retirement of Chuck Kummeth. Effective November 1, 2023, Kim Kelderman will be appointed as Chief Operating Officer of the Company. Mr. Kelderman, age 56, has served as President – Diagnostics and Genomics since he joined the Company in April 2018. Prior to joining the Company, Mr. Kelderman was an executive at Thermo Fisher Scientific and a Senior Segment Leader at Becton Dickinson. Effective February 1, 2024, Mr. Kummeth will transition from Chief Executive Officer to Senior Advisor until the date of his retirement on July 1, 2024. Mr. Kummeth will also retire from the Board of Directors on such date. Also effective February 1, 2024, Mr.

   Read the 8-K filing
9. Jan 31, 2023

   On January 26, 2022, the Compensation Committee of the Board of Directors of Bio-Techne Corporation (the “Company”) appointed Mr. Shane Bohnen, age 48, as an executive officer of the Company in the position of Senior Vice President, General Counsel and Corporate Secretary, effective March 3, 2023. Mr. Bohnen succeeds Brenda Furlow, who has announced her intention to retire on March 3, 2023. Mr. Bohnen most recently served as Associate General Counsel for the Company since 2019. Prior to joining the Company, Mr. Bohnen served as in-house corporate counsel at Resideo Technologies, Inc. beginning in 2018. From 2013 to 2018, he held roles of increasing responsibility as in-house counsel at Smiths Medical, Inc. Mr. Bohnen also was a litigation attorney for ten years, including eight years at Bowman & Brooke LLP, where he handled a broad range of litigation matters. With his appointment, Mr.

   Read the 8-K filing
10. Aug 5, 2022

    Chief Executive Officer Transition On August 4, 2022, Bio-Techne Corporation (the “Company”) announced Chuck Kummeth’s plan to retire from his position as Chief Executive Officer effective June 30, 2024, the end of the Company's 2024 fiscal year. The Board of Directors of the Company has begun the process of identifying and evaluating both internal and external candidates to assume the CEO position upon Mr. Kummeth’s retirement. Compensation Matters In connection with the adoption of executive compensation for the fiscal year ending June 30, 2023 by the Compensation Committee (the “Committee”) of the Company's Board of Directors, the Committee, in consultation with the Board of Directors, developed and approved a two-year compensation plan for Mr. Kummeth. The multi-year plan was designed to encourage Mr.

    Read the 8-K filing
11. Dec 22, 2021

    On December 17, 2021, the Compensation Committee of the Board of Directors of Bio-Techne Corporation (the “Company”) appointed Mr. William Alexander Geist, age 52, as an executive officer of the Company in the position of President, Protein Sciences Segment, effective January 3, 2022. Mr. Geist succeeds N. David Eansor, who has announced his intention to retire. Mr. Eansor will remain with the Company through the end of February 2022 to assist with transition. Mr. Geist most recently serving as Chief Operating Officer for Quanterix, where he was responsible for enterprise-wide operations and strategy deployment. Previously, from 2015 through January 2020, Mr. Geist was Vice President & General Manager for two of Thermo Fisher Scientific’s largest Business Units, Protein & Cell Analysis and qPCR. Prior to Thermo Fisher Scientific, Mr.

    Read the 8-K filing
12. Nov 3, 2020

    On October 29, 2020, Bio-Techne Corporation (the “ Company ”) held its 2020 Annual Meeting of Shareholders (the “ Annual Meeting ”). At the Annual Meeting, the Company’s shareholders approved a resolution to amend and restate the Company’s Second Amended and Restated 2010 Equity Incentive Plan (the “ Plan ” and, as amended and restated, the “ Amended Plan ”), including allocating an additional 1,300,000 shares for awards under the Amended Plan. A description of the material terms of the Amended Plan is set forth in the Company’s definitive proxy statement relating to the Annual Meeting filed with the Securities and Exchange Commission on September 15, 2020 (the “ Proxy Statement ”).

    Read the 8-K filing
13. Aug 4, 2020

    Bio-Techne Corporation has expanded the size of the Board of Directors from nine to ten members and elected Julie L. Bushman to the company’s Board of Directors as an independent director, both effective July 31, 2020. Julie L. Bushman, 59, is the former Executive Vice President of International Operations for 3M. She previously served in various executive positions at 3M, including as Senior Vice President of Business Transformation and Information Technology; Executive Vice President of Safety, Security and Protection Services; Executive Vice President of Safety and Graphics; Division Vice President of the Occupational Health and Environmental Safety Division; and Chief Information Officer. Bushman joined 3M in 1983. She currently also serves as a director of Adient plc, an automotive seating company and Phillips 66, an energy manufacturing and logistics company.

    Read the 8-K filing
14. Jun 25, 2019

    Bio-Techne Corporation has expanded the size of the Board of Directors from eight to nine members and elected Dr. Rupert Vessey to the company’s Board of Directors as an independent director. Rupert Vessey, MA, BM BCh, FRCP, DPhil is currently the President of Global Research and Early Development at Celgene, and is anticipated to hold that position at Bristol-Myers Squibb once its acquisition of Celgene is final. Before joining Celgene, Dr. Vessey held various research and development senior management positions at Merck. Dr. Vessey holds an MA in physiological sciences and a BM BCh in clinical medicine from Oxford University where he completed his DPhil at the Institute for Molecular Medicine, Oxford along with additional clinical training at various hospitals in the UK. He is a member of the Royal College of Physicians of London UK.

    Read the 8-K filing
15. Apr 24, 2018

    On April 20, 2018, Bio-Techne Corporation (the “ Company ”) appointed Kim Kelderman, age 50, as an executive officer of the Company in the position of President, Diagnostics and Genomics. This appointment is effective April 30, 2018. In his role, Mr. Kelderman will manage the Company’s Diagnostics business and will also provide guidance on our strategic initiatives in genomics and genomics-based diagnostics as the Company explores opportunities to reorganize our business structure in fiscal year 2019 to better support our businesses and facilitate global growth. For the last seven years Mr. Kelderman held various leadership roles with Thermo Fisher, most recently as leader of Platforms and Content for its Genetic Sciences Division. With his appointment, Mr.

    Read the 8-K filing

Proxy statements (DEF 14A): 2025 · 2024 · 2023 · 2022 · 2021 · 2020

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.